DAY 3 THURSDAY 23 SEPTEMBER – CLINICAL TRIALS, COLLABORATIONS & COMBINATION THERAPY DAY 3 THURSDAY 23 SEPTEMBER – CLINICAL TRIALS, COLLABORATIONS & COMBINATION THERAPY
9am Chairman’s opening remarks
Vice President Global Clinical and Medical Affairs, Baxter BioScience
IMPROVING EARLY CLINICAL TRIAL SET-UP9.10am Clinical development strategies for targeted cancer therapy
- Medical and scientific strategies for clinical development of efficacious oncology drugs – what information needs to be obtained and how to get it.
- Incorporating targeted cancer therapy into these development strategies.
- Solutions for overcoming patient selection and clinical end point challenges.
Vice President Clinical Oncology, Human Genome Sciences
9.40am Putting diagnostics into practice for effective clinical trials: what is the impact of patient stratification and narrowing the market?
- Considering the genetic heterogeneity of cancer and subsequent options for targeting the disease.
- Is the trade-off between targeting a narrower market and improved efficacy a realistic worthwhile investment?
- What steps are being taken to better tailor particular therapies to particular patients?
Senior Vice President R&D, Global Head Therapeutic Area Oncology, Merck Serono
10.10am Evaluating a Phase 1 trial and the criteria for viable progression into Phase 2 studies
- Comparative analysis of the success of Phase 1 trials and the impact on efficacy later down the line.
- How are the criteria for continuing development of a product into further clinical trials established and subsequently met?
- What are the implications of the information obtained from Phase 1 trials for the development of a marketable targeted oncology product
Vice President Oncology R&D, Biogen Idec
10.40am SATURN trial case study
Senior Vice President Pharmacuetical Operations, OSI Pharmaceuticals, a subsidary of Astellas
11.10am Morning refreshments11.40am Opportunities offered by Merck’s scientifically-driven licensing models in oncology
- Opportunity for biotech: what kind of opportunities is the company looking to bring in?
- Understanding the broad assortment of deal-types available with examples.
- Opportunity for Big Pharma: what can be learned from Merck’s intelligent approach to partnerships and licensing in the oncology space?
Senior Director and Head of Licensing and External Research, Merck & Co
12.10pm The Innovative Medicines Initiative: reinvigorating biopharmaceuticals for oncology in Europe via a unique collaborative strategy
- Understanding the Initiative: practical solutions for instigating collaboration in R&D between Big Pharma in Europe.
- Overcoming industrial and scientific challenges in cancer research at the European level.
- An update on progress: what steps have been taken to place Europe at the forefront of the oncology industry?
Executive Director, Innovative Medicines Initiative
12.40pm Managing the dynamics of alliances and collaborations: co-development of targeted cancer therapeutics
- Making your partnership work
- Gefitinib case: lessons learned
- Achieving success in Personalised health care approach; the role of partnerships.
Global Brand Physician, AstraZeneca Pharmaceuticals
NOVEL COMBINATION TARGETED THERAPIES2pm Systematic discovery of novel combination targets and therapeutics
- Employing a systematic approach to the discovery of novel targets and pathway interactions specific to cancer biology.
- Considering chemical biology and genomics data to drive hypothesis generation applicable to patient selection and combination therapeutic development.
- Where to go from here – what is required to push novel mechanism discovery towards co-development of more selective and efficacious combination therapeutics?
Vice President Therapeutic Area Research, CombinatoRx Incorporated
2.30pm Panel discussion with Q&A: strategies for the early development of novel combined targeted cancer therapy
- Comparing the approaches taken by Big Pharma and biotech to development novel combined targeted therapies – advantages and disadvantages.
- Strategies for managing early co-development of targeted cancer drugs: scientifically, clinically and strategically.
- Future options and aspirations.
Vice President Therapeutic Area Research, CombinatoRx Incorporated Global Brand Physician, AstraZeneca Pharmaceuticals
3pm Afternoon refreshments SOLUTIONS FOR THE NEXT GENERATION OF TARGETED CANCER THERAPY3.30pm Extended panel discussion with Q&A: how is big pharma driving targeted cancer therapies to the forefront of the oncology industry?
- Scientifically – what are the areas of greatest potential for further development? Which industry profiles hold the key to developing them?
- Clinically – has the time come to readdress how oncology trials are planned and executed? What are the alternatives?
- Commercially – how can we integrate science and clinical outcomes into a successful business plan that meets the requirements of drug developers, patients, clinicians and government?
Vice President Oncology R&D, Biogen Idec Senior Vice President R&D, Global Head Therapeutic Area Oncology, Merck Serono Vice President Clinical Oncology, Human Genome Sciences Global Brand Physician, AstraZeneca Pharmaceuticals
|
|
|
|
|
Conference:
Day 1
September 21, 8:30am - 5:30pm
Day 2
September 22, 8:30am - 5:30pm
Day 3
September 23, 9am - 5:30pm
|
|
|
